Calithera Biosciences Inc. recently revealed Phase 1 study results of candidate CB-839, potential treatment for certain advanced breast cancers, based on its potential efficacy when used with the chemotherapy medication paclitaxel.
The regimen works by inhibiting glutaminase and is specifically developed for patients living with advanced and/or metastatic triple negative breast cancer (TNBC), according to a Calithera press release.
“Effective treatment for triple negative breast cancer in the advanced and metastatic population remains a significant unmet need,” Susan Molineaux, Calithera’s president and CEO, said in the release. “In our Phase 1 study, we were pleased to have observed responses in patients who were heavily pretreated and the Phase 2 study will help us further understand the role of CB-839 in inhibiting glutaminase to help control the progression of cancer in advanced metastatic TNBC patients.”
The announcement coincided with a poster presentation from Columbia University Medical Center’s Dr. Kevin Kalinsky titled “Phase I study of CB-839, a first-in-class inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer."
Calithera presented the results at the recent 2017 San Antonio Breast Cancer Symposium in Texas.
